146 related articles for article (PubMed ID: 15865101)
1. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer.
Patlakas G; Bouros D; Tsantekidou-Pozova S; Koukourakis MI
Anticancer Res; 2005; 25(2B):1427-31. PubMed ID: 15865101
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Pectasides D; Aspropotamitis A; Halikia A; Visvikis A; Antoniou F; Kalantaridou A; Karvounis N; Batzios S; Athanassiou A
J Clin Oncol; 1999 Dec; 17(12):3816-21. PubMed ID: 10577854
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Hejna M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger WC; Marosi L; Schneeweiss B; Greul R; Scheithauer W
Cancer; 2000 Aug; 89(3):516-22. PubMed ID: 10931450
[TBL] [Abstract][Full Text] [Related]
5. Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.
Koukourakis MI; Romanidis K; Froudarakis M; Kyrgias G; Koukourakis GV; Retalis G; Bahlitzanakis N
Br J Cancer; 2002 Aug; 87(4):385-92. PubMed ID: 12177774
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
7. Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Ardizzoia A; Acquati M; Fagnani D; Giordano M; Visini M; Scanni A; Quattrone A; Fusco O; Vergani C; Casartelli C; Tagliabue P; Malugani F;
Lung; 2004; 182(1):1-8. PubMed ID: 14752667
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
10. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Georgoulias V; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Palamidas P; Vlachonikolis I;
Lancet; 2001 May; 357(9267):1478-84. PubMed ID: 11377599
[TBL] [Abstract][Full Text] [Related]
11. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Georgoulias V; Kouroussis C; Androulakis N; Kakolyris S; Dimopoulos MA; Papadakis E; Bouros D; Apostolopoulou F; Papadimitriou C; Agelidou A; Hatzakis K; Kalbakis K; Kotsakis A; Vardakis N; Vlachonicolis J
J Clin Oncol; 1999 Mar; 17(3):914-20. PubMed ID: 10071284
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Koukourakis MI; Giatromanolaki A; Kakolyris S; Froudarakis M; Georgoulias V; Retalis G; Bahlitzanakis N
Med Oncol; 2000 May; 17(2):135-43. PubMed ID: 10871820
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
De Castro J; Lorenzo A; Morales S; Belón J; Dorta J; Lizón J; Madroñal C; Gallurt PM; Casado E; Feliu J; Barón MG;
Cancer Chemother Pharmacol; 2005 Feb; 55(2):197-202. PubMed ID: 15322824
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Chen YM; Perng RP; Lin WC; Wu HW; Tsai CM; Whang-Peng J
Am J Clin Oncol; 2002 Oct; 25(5):509-12. PubMed ID: 12393994
[TBL] [Abstract][Full Text] [Related]
15. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.
Illiano A; Barletta E; De Marino V; Battiloro C; Barzelloni M; Scognamiglio F; Rossi N; Zampa G; De Bellis M; Gridelli C
Anticancer Res; 2000; 20(5C):3999-4003. PubMed ID: 11268491
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR;
Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group.
Katakami N; Takiguchi Y; Yoshimori K; Isobe H; Bessho A; Yoshimura A; Niitani H
J Thorac Oncol; 2006 Jun; 1(5):447-53. PubMed ID: 17409898
[TBL] [Abstract][Full Text] [Related]
18. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
Tibaldi C; Vasile E; Antonuzzo A; Di Marsico R; Fabbri A; Innocenti F; Tartarelli G; Amoroso D; Andreuccetti M; Lo Dico M; Falcone A
Br J Cancer; 2008 Feb; 98(3):558-63. PubMed ID: 18212755
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
Georgoulias V; Ardavanis A; Tsiafaki X; Agelidou A; Mixalopoulou P; Anagnostopoulou O; Ziotopoulos P; Toubis M; Syrigos K; Samaras N; Polyzos A; Christou A; Kakolyris S; Kouroussis C; Androulakis N; Samonis G; Chatzidaki D
J Clin Oncol; 2005 May; 23(13):2937-45. PubMed ID: 15728228
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]